(Q38053000)

27 August 2017

title

Is repositioning of drugs a viable alternative in the treatment of tuberculosis? (English)

1 reference

27 August 2017

0 references

Juan Carlos Palomino

1

1 reference

27 August 2017

Anandi Martin

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

16 October 2012

1 reference

Journal of Antimicrobial Chemotherapy

27 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

27 August 2017

volume

68

1 reference

27 August 2017

issue

2

1 reference

27 August 2017

page(s)

275-283

1 reference

Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

HIV infection and multidrug-resistant tuberculosis: the perfect storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Global tuberculosis drug development pipeline: the need and the reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Totally drug-resistant tuberculosis in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Fourteen years in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

A major genome region underlying artemisinin resistance in malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Low hanging fruit in infectious disease drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Trends in antimicrobial drug development: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

MRSA: the first half century

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Resistance drives antibacterial drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Quinolone antibacterials. An update of their pharmacology and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Plasmid-Mediated Quinolone Resistance; Interactions between Human, Animal, and Environmental Ecologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Emergence of fluoroquinolone-resistant tuberculosis in New York City.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Fluoroquinolones in the management of community-acquired pneumonia in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Current prospects for the fluoroquinolones as first-line tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Linezolid, the first oxazolidinone antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Efficacy of linezolid versus comparator therapies in Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Linezolid for the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

First linezolid-resistant clinical isolates of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Tuberculosis and trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Reconsidering some approved antimicrobial agents for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Treatment of Mycobacterium marinum cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mycobacterium tuberculosis and sulfamethoxazole susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Trimethoprim-sulfamethoxazole revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Genetic requirements for mycobacterial survival during infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Clofazimine: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Imipenem for treatment of tuberculosis in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Activity of carbapenems combined with clavulanate against murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Antimalarial Activities of Various 4-Quinolinemethanols with Special Attention to WR-142,490 (Mefloquine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

The potential management of resistant infections with non-antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

"Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Estimating the cost of new drug development: is it really 802 million dollars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

New anti-tuberculosis drugs: strategies, sources and new molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Exploiting drug-disease relationships for computational drug repositioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

Mechanism of action of and resistance to quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS405

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS405

1 reference

27 August 2017

1 reference